BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin and Özlem Türeci will ...
Mainz, Germany, March 10, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced plans for an independent company to be established and led by BioNTech ...
Hosted on MSN
CureVac sues Moderna in escalating mRNA patent fight
CureVac, now owned by BioNTech, has filed an eight-patent infringement lawsuit against Moderna in Delaware, alleging Spikevax used its mRNA stabilization technology without permission. The case is ...
The treatment staved off cancer for seven of eight patients with a condition where the odds are rarely that good.
The EMA has recommended updating Comirnaty 10 mg formulations, including JN.1, KP.2, and LP.8.1 versions, to allow COVID-19 vaccination in individuals aged 6 months or older.
The world could be only a few years away from a cancer vaccine, according to the couple behind the Pfizer/BioNtech COVID-19 vaccine. "We feel that a cure for cancer or to changing cancer patients' ...
One of the paradoxically beneficial consequences of the COVID pandemic was that even without the compulsory aspects of the vaccine patent waiver proposed by certain WTO member states (Brazil, India, ...
Moderna (MRNA) faces a lawsuit in the U.S. for allegedly infringing patent rights related to the COVID-19 shot developed by Pfizer (PFE) and BioNTech (BNTX), marking the latest such case among ...
BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin and Özlem Türeci will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results